These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease. Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459 [TBL] [Abstract][Full Text] [Related]
5. Deterioration of severe Graves' ophthalmopathy during cyclosporin treatment. Howlett TA; Lawton NF; Fells P; Besser GM Lancet; 1984 Nov; 2(8411):1101. PubMed ID: 6150174 [No Abstract] [Full Text] [Related]
6. Correlation of orbital computed tomography and antibodies in patients with hyperthyroid Graves' disease. Chang TC; Huang KM; Chang TJ; Lin SL Clin Endocrinol (Oxf); 1990 May; 32(5):551-8. PubMed ID: 2194711 [TBL] [Abstract][Full Text] [Related]
7. Treatment of Graves' ophthalmopathy with cyclosporin A. Kvetny J; Frandsen NE; Johnsen T; Dieperinck H; Mogensen E Acta Med Scand; 1986; 220(2):189-91. PubMed ID: 3535393 [TBL] [Abstract][Full Text] [Related]
8. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy. Kendall-Taylor P; Crombie AL; Stephenson AM; Hardwick M; Hall K BMJ; 1988 Dec; 297(6663):1574-8. PubMed ID: 2906260 [TBL] [Abstract][Full Text] [Related]
9. Antithyroglobulin monoclonal and autoantibodies cross-react with an orbital connective tissue membrane antigen: a possible mechanism for the association of ophthalmopathy with autoimmune thyroid disorders. Kuroki T; Ruf J; Whelan L; Miller A; Wall JR Clin Exp Immunol; 1985 Nov; 62(2):361-70. PubMed ID: 3841305 [TBL] [Abstract][Full Text] [Related]
10. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448 [TBL] [Abstract][Full Text] [Related]
12. The behaviour of suppressor-inducer T cells following treatment for Graves' disease. Wilson R; Pearson C; McKillop JH; Burnett AK; Thomson JA Autoimmunity; 1990; 6(1-2):93-7. PubMed ID: 2151791 [TBL] [Abstract][Full Text] [Related]
13. Analysis of peripheral T lymphocyte subpopulations in Graves' disease. Okabe N; Inoue K; Mori R J Clin Lab Immunol; 1983 Feb; 10(2):91-5. PubMed ID: 6221106 [TBL] [Abstract][Full Text] [Related]
14. [Immunologic analysis of Graves' ophthalmopathy and ophthalmic Graves' disease]. Liao ZQ Zhonghua Yan Ke Za Zhi; 1990 May; 26(3):162-4. PubMed ID: 2144488 [TBL] [Abstract][Full Text] [Related]
15. Time-dependent effect of cyclosporin-A on the TSH-receptor antibody synthesis in patients with Graves' disease. Balázs C; Kiss E; Farid NR Acta Med Hung; 1988; 45(1):43-52. PubMed ID: 3412862 [TBL] [Abstract][Full Text] [Related]
17. Treatment of severe Graves' ophthalmopathy with cyclosporin A. Utech C; Wulle KG; Bieler EU; Pfannenstiel P; Panitz N; Kiefer H Acta Endocrinol (Copenh); 1985 Dec; 110(4):493-8. PubMed ID: 3911714 [TBL] [Abstract][Full Text] [Related]
18. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism. Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210 [TBL] [Abstract][Full Text] [Related]
19. Affinity purification of orbital membrane antigens for the study of the pathogenesis of Graves' ophthalmopathy. Salvi M; Bingoye F; Chung F; Wall JR J Clin Endocrinol Metab; 1988 May; 66(5):939-45. PubMed ID: 3360902 [TBL] [Abstract][Full Text] [Related]